Introduction Stroma cells and extracellular matrix (ECM) components provide the pivotal microenvironment for tumor development. The study aimed to evaluate the importance of the pancreatic stroma for tumor development. Methods Pancreatic tumor cells were implanted subcutaneously into green fluorescent protein transgenic mice, and stroma cells invading the tumors were identified through immunohistochemistry. Inhibition of tumor invasion by stroma cells was achieved with halofuginone, an inhibitor of TGFβ/Smad3 signaling, alone or in combination with chemotherapy. The origin of tumor ECM was evaluated with species-specific collagen I antibodies and in situ hybridization of collagen α1(I) gene. Pancreatic fibrosis was induced by cerulean injection and tumors by spleen injection of pancreatic tumor cells. Results Inhibition of stroma cell infiltration and reduction of tumor ECM levels by halofuginone inhibited development of tumors derived from mouse and human pancreatic cancer cells. Halofuginone reduced the number only of stroma myofibroblasts expressing both contractile and collagen biosynthesis markers. Both stroma myofibroblasts and tumor cells generated ECM that contributes to tumor growth. Combination of treatments that inhibit stroma cell infiltration, cause apoptosis of myofibroblasts and inhibit Smad3 phosphorylation, with chemotherapy that increases tumor-cell apoptosis without affecting Smad3 phosphorylation was more efficacious than either treatment alone. More tumors developed in fibrotic than in normal pancreas, and prevention of tissue fibrosis greatly reduced tumor development. Conclusions The utmost importance of tissue fibrosis and of stroma cells for tumor development presents potential new therapy targets, suggesting combination therapy against stroma and neoplastic cells as a treatment of choice.
References
[1]
Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth Oncogene 27: 5904–5912.
[2]
van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82: 539–548.
[3]
Alphonso A, Alahari SK (2009) Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia 11: 1264–1271.
[4]
Shekhar MP, Pauley R, Heppner G (2003) Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res 5: 130–135.
[5]
Desmouliere A, Guyot CH, Gabbiani G (2004) The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol 48: 509–517.
[6]
Radisky DC, Kenny PA, Bissell MJ (2007) Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 101: 830–839.
[7]
Liu M, Xu J, Deng H (2011) Tangled fibroblasts in tumor-stroma interactions. Int J Cancer 129(8): 1795–1805.
[8]
Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L (2001) Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 61: 1320–1326.
[9]
Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE (2001) Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res 61: 2328–2334.
[10]
Spector I, Honig H, Kawada N, Nagler A, Genin O, et al. (2010) Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development. Pancreas 39: 1008–1015.
[11]
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335–348.
[12]
Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, et al. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68: 918–916.
[13]
van Hoorde L, van Aken E, Mareel M (2000) Collagen type I: a substrate and a signal for invasion. Prog Mol Subcell Biol 25: 105–134.
[14]
Zidar N, Gale N, Kambic V, Kambic V, Fischinger J (2002) Proliferation of myofibroblasts in the stroma of epithelial hyperplastic lesions and squamous carcinoma of the larynx. Oncology 62: 381–385.
[15]
Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, et al. (2004) Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 10: 7427–7437.
[16]
Imamichi Y, Menke A (2007) Signaling pathways involved in collagen-induced disruption of the E-cadherin complex during epithelial–mesenchymal transition. Cells Tiss Org 185: 180–190.
[17]
Cheng JC, Leung PC (2011) Type I collagen down-regulates E-cadherin expression by increasing PI3KCA in cancer cells. Cancer Lett 304: 107–116.
[18]
Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6: 392–401.
[19]
De Wever O, Mareel M (2002) Role of myofibroblasts at the invasion front. Biol Chem 383: 55–67.
[20]
Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, et al. (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8: 2912–2923.
[21]
Micke P, Ostman A (2004) Tumor-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer. pp. S163–175.
[22]
Rosenthal E, McCrory A, Talbert M, Young G, Murphy-Ullrich J, et al. (2004) Elevated expression of TGF-beta1 in head and neck cancer-associated fibroblasts. Mol Carcinogen 40: 116–121.
[23]
Webber J, Steadman R, Mason MD, Tabi Z, Clayton A (2010) Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 70: 9621–9630.
[24]
Untergasser G, Gander R, Lilg C, Lepperdinger G, Plas E, et al. (2005) Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Aging Dev 126: 59–69.
[25]
Chu GC, Kimmelman AC, Hezel AF, DePinho RA (2007) Stromal biology of pancreatic cancer. J Cell Biochem 101: 887–907.
[26]
Wu SD, Ma YS, Fang Y, Liu LL, Fu D, et al. (2012) Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev 38(3): 218–225.
[27]
Yang JD, Nakamura I, Roberts LR (2011) The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 21: 35–43.
[28]
Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, et al. (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128: 907–921.
[29]
Amann T, Bataille F, Spruss T, Mühlbauer M, G？bele E, et al. (2009) Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 100: 646–653.
[30]
Xia Y, Chen R, Song Z, Ye S, Sun R, et al. (2010) Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum. J Cancer Res Clin Oncol 136: 309–321.
[31]
Erkan M, Reiser-Erkan C, Michalski CW, Kleeff J (2010) Tumor microenvironment and progression of pancreatic cancer. Exp Oncol 32: 128–131.
[32]
Apte MV, Park S, Phillips PA, Santucci N, Goldstein D, et al. (2004) Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 29: 179–187.
[33]
McGaha TL, Phelps RG, Spiera H, Bona C (2002) Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118: 461–470.
[34]
Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, et al. (2004) Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 279: 15167–15176.
[35]
Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, et al. (2001) Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33: 379–386.
[36]
Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, et al. (2007) Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tiss Res 328: 153–166.
[37]
Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, et al. (2009) Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 38: 427–435.
[38]
Sheffer Y, Leon O, Pinthus JH, Nagler A, Mor Y, et al. (2007) Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated anti-tumoral effect. Mol Cancer Ther 6: 570–577.
[39]
Genin O, Rechavi G, Nagler A, Ben-Itzhak O, Nazemi KJ, et al. (2008) Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment? Neoplasia 10: 940–948.
[40]
Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M (1999) Inhibition of neovascularization, tumor growth and facilitation of wound repair by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1: 321–329.
[41]
Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, et al. (2002) Growth inhibition of prostate cancer xenografts by halofuginone. Prostate 51: 73–83.
[42]
Pinthus JH, Sheffer Y, Nagler A, Fridman E, Mor Y, et al. (2005) Inhibition of Wilms tumor xenografts progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol 174: 1527–1531.
[43]
Friedman SL (2004) Stellate cells: a moving target in hepatic fibrogenesis. Hepatology 40: 1041–1043.
[44]
Masamune A, Watanabe T, Kikuta K, Shimosegawa T (2009) Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol 7(11 Suppl). pp. S48–54.
[45]
Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I (2008) Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 55: 2016–2027.
[46]
Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, et al. (2011) Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract 207: 8–14.
[47]
van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G (2009) Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 28: 4022–4033.
[48]
Sugimoto H, Mundel TM, Kieran MW, Kalluri R (2006) Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5: 1640–1646.
Ikenaga N, Ohuchida K, Mizumoto K, Cui L, Kayashima T, et al. (2010) CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology 139: 1041–1051.
[51]
Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, et al. (2011) Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 71: 1272–1281.
[52]
Medici D, Nawshad A (2010) Type I collagen promotes epithelial-mesenchymal transition through ILK-dependent activation of NF-kappaB and LEF-1. Matrix Biol 29: 161–165.
[53]
Mikula M, Proell V, Fischer AN, Mikulits W (2006) Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 209: 560–567.
[54]
Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, et al. (2004) Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28: 38–44.
[55]
Müerk？ster S, Wegehenkel K, Arlt A, Witt M, Sipos B, et al. (2004) Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1h. Cancer Res 64: 1331–1337.
[56]
Adegboyega PA, Rodriguez S, McLarty J (2010) Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma. Hum Pathol 41: 1128–1137.
[57]
Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86: 1065–1073.
[58]
Pines M, Domb A, Ohana M, Inbar J, Genina O, et al. (2001) Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol 62: 1221–1227.
[59]
Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA (2012) What we have learned about pancreatic cancer from mouse models. Gastroenterology 142(5): 1079–1092.
[60]
Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, et al. (2012) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut [Epub ahead of print].
[61]
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, et al. (2009) Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science 324 (5933): 1457–1461.
[62]
Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG (2012) Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J 441(2): 541–552.
[63]
Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE (2008) Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am J Physiol Heart Circ Physiol. 294(4): H1550–H1561.
[64]
Nagler A, Pines M (1999) Topical treatment of cutaneous chronic graft versus host disease (cGvHD) with halofuginone: A novel inhibitor of collagen type I synthesis. Transplantation 68: 1806–1809.
[65]
Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, et al. (2009) Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 324(5932): 1334–1338.
[66]
Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, et al. (2012) Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol 8(3): 311–317.
